Regeneron Pharmaceuticals PE ratio REGN

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: 19.9×
10-year median: 19.7×
Against its 10-year history: 52nd; percentile: 0 is its lowest day, 100 its highest
10-year range: 8.1× to 62.3×
Peer median: 34.0×

Regeneron Pharmaceuticals' PE ratio is 19.9× as of Oct 23, 2026: a share price of $805.02 against $40.44 of earnings per share over the last twelve months.

That is above its ten-year median of 19.7×, close to the middle of its last ten years.

Over that time it ranged from 8.1× in Jun 2022 to 62.3× in Jun 2017.

The median for 10 biotech stocks of a similar size is 34.0×.

PE ratio over time

median 19.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	19.9×	14.9×	20.6×
2025	18.8×	12.5×	18.8×
2024	17.6×	17.4×	32.5×
2023	25.1×	15.2×	25.1×
2022	15.2×	8.1×	16.2×
2021	10.1×	9.8×	19.7×
2020	17.7×	17.5×	32.4×
2019	20.0×	13.8×	27.5×
2018	23.2×	21.8×	35.0×
2017	34.1×	33.9×	62.3×
2016	54.4×	50.6×	95.8×
2015	106×	104×	176×
2014	140×	38.7×	144×
2013	39.5×	24.3×	92.9×
2012	86.1×	72.2×	92.8×

Against its peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

Company	PE ratio
REGNRegeneron Pharmaceuticals	19.9×
VRTXVertex Pharmaceuticals	30.5×
ONCBeOne Medicines	67.6×
ALNYAlnylam Pharmaceuticals	37.8×
UTHRUnited Therapeutics	21.0×
INCYIncyte	14.7×
EXELExelixis	20.3×
NBIXNeurocrine Biosciences	20.9×
HALOHalozyme Therapeutics	37.5×
TECHBIO-TECHNE	63.1×
RGENRepligen	242×
Peer median	34.0×

Where Regeneron Pharmaceuticals ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Regeneron Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.